Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Superinvestors holding FATE, Q2 2026
No superinvestor reported holding FATE in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of FATE each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q1 2023
0 superinvestors holding at quarter end
- Sold out
- ARK Invest
Q4 2022
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−63.8%)
Q3 2022
1 superinvestor holding at quarter end
- Added
- ARK Invest (+1.6%)
Q2 2022
1 superinvestor holding at quarter end
- Added
- ARK Invest (+4.4%)
Q1 2022
1 superinvestor holding at quarter end
- Added
- ARK Invest (+6.6%)
Q4 2021
1 superinvestor holding at quarter end
- Reduced
- ARK Invest (−5.4%)
- Sold out
- Lone Pine Capital
Q3 2021
2 superinvestors holding at quarter end
- Added
- ARK Invest (+45.7%), Lone Pine Capital (+25.7%)
Q2 2021
2 superinvestors holding at quarter end
- Added
- ARK Invest (+14.2%)